• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R.

作者信息

Lakhotia Rahul, Dunleavy Kieron, Abramson Jeremy S, Link Brian K, Powell Bayard L, Melani Christopher, Lucas Andrea N, Steinberg Seth M, Friedberg Jonathan W, Kahl Brad S, Little Richard F, Bartlett Nancy L, Noy Ariela, Wilson Wyndham H, Roschewski Mark

机构信息

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.

Department of Hematology-Oncology, Georgetown University, Washington, DC.

出版信息

Blood Adv. 2023 Sep 26;7(18):5320-5324. doi: 10.1182/bloodadvances.2023010223.

DOI:10.1182/bloodadvances.2023010223
PMID:37389844
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10506053/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ecc/10506053/2e9e6868088b/BLOODA_ADV-2023-010223-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ecc/10506053/71a6e3ffe56e/BLOODA_ADV-2023-010223-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ecc/10506053/3d63ba9ae240/BLOODA_ADV-2023-010223-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ecc/10506053/2e9e6868088b/BLOODA_ADV-2023-010223-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ecc/10506053/71a6e3ffe56e/BLOODA_ADV-2023-010223-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ecc/10506053/3d63ba9ae240/BLOODA_ADV-2023-010223-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ecc/10506053/2e9e6868088b/BLOODA_ADV-2023-010223-gr2.jpg

相似文献

1
Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R.接受剂量调整的EPOCH-R方案治疗的成年伯基特淋巴瘤患者的预后因素
Blood Adv. 2023 Sep 26;7(18):5320-5324. doi: 10.1182/bloodadvances.2023010223.
2
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.成人初治伯基特淋巴瘤采用剂量调整型EPOCH-R进行风险适应性治疗的多中心研究。
J Clin Oncol. 2020 Aug 1;38(22):2519-2529. doi: 10.1200/JCO.20.00303. Epub 2020 May 26.
3
Low-intensity therapy in adults with Burkitt's lymphoma.成人伯基特淋巴瘤的低强度治疗。
N Engl J Med. 2013 Nov 14;369(20):1915-25. doi: 10.1056/NEJMoa1308392.
4
Dose-adjusted EPOCH-R: a feasible alternative for Burkitt lymphoma in resource-constrained settings.剂量调整的EPOCH-R方案：资源受限环境下伯基特淋巴瘤的一种可行替代方案
Br J Haematol. 2020 Sep;190(6):e362-e363. doi: 10.1111/bjh.16921. Epub 2020 Jul 2.
5
Successful Use of EPOCH-R in 2 Young Adult Patients With Burkitt Lymphoma and Acute Kidney Injury: A Case Report.EPOCH-R方案在2例患有伯基特淋巴瘤和急性肾损伤的年轻成年患者中的成功应用：病例报告
J Pediatr Hematol Oncol. 2019 Aug;41(6):498-500. doi: 10.1097/MPH.0000000000001287.
6
[Clinical Efficacy and Prognostic Factors of Newly Diagnosed Children[JP] with Burkitt Lymphoma Treated by High-Dose and Short-Course Modified LMB Regimen ± Rituximab].[大剂量短疗程改良LMB方案±利妥昔单抗治疗新诊断儿童伯基特淋巴瘤的临床疗效及预后因素[日文]]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Apr;28(2):529-534. doi: 10.19746/j.cnki.issn.1009-2137.2020.02.029.
7
Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.利妥昔单抗联合化疗治疗中枢神经系统和/或骨髓阳性的儿童及青少年伯基特淋巴瘤/白血病：儿童肿瘤学组报告
Br J Haematol. 2014 Nov;167(3):394-401. doi: 10.1111/bjh.13040. Epub 2014 Jul 26.
8
A rapidly growing lymphoma and tumor lysis syndrome in a toddler.一名幼儿身上迅速发展的淋巴瘤及肿瘤溶解综合征。
JAAPA. 2010 Aug;23(8):30, 32-4. doi: 10.1097/01720610-201008000-00007.
9
A case of primary gastric Burkitt-like lymphoma with chemotherapy-induced perforation.
Turk J Gastroenterol. 2012 Jun;23(3):299-300. doi: 10.4318/tjg.2012.0373.
10
Burkitt lymphomas failing dose-adjusted R-EPOCH (DA-R-EPOCH).对剂量调整的R-EPOCH（DA-R-EPOCH）治疗无效的伯基特淋巴瘤。
Ann Hematol. 2014 Jan;93(1):177-8. doi: 10.1007/s00277-013-1771-8. Epub 2013 May 2.

本文引用的文献

1
Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma.遗传亚群为成人和儿童伯基特淋巴瘤的病理生物学提供信息。
Blood. 2023 Feb 23;141(8):904-916. doi: 10.1182/blood.2022016534.
2
Burkitt's Lymphoma.伯基特淋巴瘤
N Engl J Med. 2022 Sep 22;387(12):1111-1122. doi: 10.1056/NEJMra2025746.
3
Burkitt Lymphoma International Prognostic Index.Burkitt 淋巴瘤国际预后指数。
J Clin Oncol. 2021 Apr 1;39(10):1129-1138. doi: 10.1200/JCO.20.03288. Epub 2021 Jan 27.
4
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.现代时代的伯基特淋巴瘤：30 家美国癌症中心的真实世界结局和预后。
Blood. 2021 Jan 21;137(3):374-386. doi: 10.1182/blood.2020006926.
5
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.利妥昔单抗治疗高危、成熟 B 细胞非霍奇金淋巴瘤患儿。
N Engl J Med. 2020 Jun 4;382(23):2207-2219. doi: 10.1056/NEJMoa1915315.
6
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.成人初治伯基特淋巴瘤采用剂量调整型EPOCH-R进行风险适应性治疗的多中心研究。
J Clin Oncol. 2020 Aug 1;38(22):2519-2529. doi: 10.1200/JCO.20.00303. Epub 2020 May 26.
7
Excellent outcomes in children and adolescents with CNS Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1.仅使用鞘内和全身化学免疫疗法治疗中枢神经系统伯基特淋巴瘤或其他成熟B细胞非霍奇金淋巴瘤的儿童和青少年患者取得了优异疗效：来自FAB/LMB96和儿童肿瘤协作组ANHL01P1研究的结果
Br J Haematol. 2019 Apr;185(2):374-377. doi: 10.1111/bjh.15520. Epub 2018 Aug 16.
8
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.利妥昔单抗联合剂量密集化疗治疗成人伯基特淋巴瘤：一项随机、对照、开放标签、3 期临床试验。
Lancet. 2016 Jun 11;387(10036):2402-11. doi: 10.1016/S0140-6736(15)01317-3. Epub 2016 Apr 11.
9
Low-intensity therapy in adults with Burkitt's lymphoma.成人伯基特淋巴瘤的低强度治疗。
N Engl J Med. 2013 Nov 14;369(20):1915-25. doi: 10.1056/NEJMoa1308392.
10
Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database.基于人群的伯基特淋巴瘤患者生存预后因素：来自监测、流行病学和最终结果数据库的分析。
Cancer. 2013 Oct 15;119(20):3672-9. doi: 10.1002/cncr.28264. Epub 2013 Jul 30.